Details of the Drug Combination

General Information of Drug Combination (ID: DC0ABT2)

• Drug Combination Name: Oxytocin + Carbetocin
• Indication: CARBETOCIN FOR PREVENTION OF PLACENTAL RETAINED; Status: Phase 4 [1]
• Component Drugs:
  Oxytocin (DMDL27I): Small molecular drug
  Carbetocin (DMUSLW3): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Oxytocin

Disease Entry	ICD 11	Status	REF
Autism spectrum disorder	6A02	Approved	[2]
Ductal breast carcinoma in situ	N.A.	Approved	[3]
Postpartum haemorrhage	JA43	Approved	[3]
Lactation failure	JB46.3	Phase 3	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[5]

Oxytocin Interacts with 4 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Agonist	[7]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Agonist	[8]
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Agonist	[9]
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Modulator	[10]

Oxytocin Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Krueppel-like factor 4 (KLF4)	OT4O9RQW	KLF4_HUMAN	Increases Expression	[11]

Indication(s) of Carbetocin

Disease Entry	ICD 11	Status	REF
Postpartum haemorrhage	JA43	Approved	[6]

Carbetocin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Agonist	[12]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Postpartum Hemorrhage	DCSPUVW	N. A.	Phase 1	[13]
Postpartum Hemorrhage	DC0F4ZF	N. A.	Phase 1	[14]

References

• [1] ClinicalTrials.gov (NCT01827124) Randomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2174).
• [3] Oxytocin FDA Label
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039450)
• [5] Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19)
• [6] Clinical Textbook of Dental Hygiene and Therapy. 2006, P237. By Robert Ireland.
• [7] The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
• [9] Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
• [11] Oxytocin inhibits ox-LDL-induced adhesion of monocytic THP-1 cells to human brain microvascular endothelial cells. Toxicol Appl Pharmacol. 2017 Dec 15;337:104-110. doi: 10.1016/j.taap.2017.10.022. Epub 2017 Nov 2.
• [12] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
• [13] ClinicalTrials.gov (NCT06285409) Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
• [14] ClinicalTrials.gov (NCT01689298) Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment